{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"Tesla shareholders approve Elon Musk’s $1 trillion pay deal — but can he deliver?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba036a1a8cbef5973cf0c0/1762537871500-5b3b986c-8cc3-4fa5-8847-dba52536e422.jpeg?height=200","description":"

Elon Musk, already the world’s richest man, has had a record-breaking pay deal approved — one that could be worth nearly $1 trillion.


At Tesla’s annual meeting in Texas, 75% of shareholders backed the move, giving Musk what’s believed to be the biggest compensation package in corporate history.


But over the next decade, will he hit the huge goals needed to earn it?


Sir Keir Starmer has told COP30 that the UK is “all in” on net zero.


Speaking in Belem, the gateway to the Brazilian Amazon, the Prime Minister said clean energy is key to jobs, growth, and climate security.


It comes as the UN warns 2025 is set to be the second or third hottest year on record, after an “unprecedented streak” of global heat.


The University of Cambridge is offering a new, minimally invasive enzyme injection to treat a severe spinal disease in dogs — the first and only treatment of its kind in the UK.


The injection has been said to have an exceptional success rate.


It targets intervertebral disc disease, which affects around a quarter of dachshunds.


We’ll hear from Professor Paul Freeman at Cambridge’s Veterinary School, who co-developed the treatment with colleagues at Texas A&M University.


Also in this episode:






","author_name":"The Evening Standard"}